Home » Stocks » NLSP

NLS Pharmaceutics Ltd. (NLSP)

NLS Pharmaceutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.00 - $6.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 58.28M
Revenue (ttm) n/a
Net Income (ttm) -5.45M
Shares Out 10.60M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 58.28M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 10.60M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.51
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -9.35%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -5.45M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Year201920182017
Revenue000
Net Income / Loss-5,447,000-5,147,000-6,657,000
Numbers in USD.

Company Profile

Company Details

Full Name NLS Pharmaceutics Ltd.
Country Switzerland
Employees 5
CEO Alexander Zwyer

Stock Information

Ticker Symbol NLSP
Stock Exchange NASDAQ
Unique Identifier NASDAQ: NLSP
IPO Date Pending

Description

NLS Pharmaceutics is an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. According to the World Health Organization and based on data from the Global Burden of Disease Report, 25% of the world’s population suffers from at least one CNS disorder, resulting in a socio-economic burden of more than $317 billion annually in the United States alone. Additionally, CNS disorders are expected to account for approximately 15% of the global disease burden by 2020, the largest burden of any disease area. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind other therapeutic areas. We are pursuing the development of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need. Our dual development strategy is designed to optimize the outcome of our clinical programs by developing new chemical entities from known molecules with strong scientific rationale, and also by re-defining previously approved molecules with well-established tolerability and safety profiles, as determined by applicable regulatory agencies. We believe that our streamlined clinical development approach has the potential to advance rapidly through early-stage clinical trials, while carrying a lower development risk.